Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Polaris Group
Asia Deal Watch: Kelun Partners With Merck A Third Time, Optioning Rights To Seven ADCs
Already partnered on antibody-drug conjugates and a Phase III breast cancer candidate, Merck could pay up to $9.3bn under its third pact in 2022 with Kelun. Eisai divests Fycompa to Catalyst.
Deal Watch: Roche, PhoreMost Enter Into Multi-Target Collaboration
Plus deals with Synaffix/Emergence, Helsinn/Juniper and Sanyou/Shanghai KangaBio, while Takeda/Finch and Dong-A/Beactica ended prior collaborations.
Pipeline Watch: Phase III Progress With Semaglutide, Tecentriq And Epidaza
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Bristol's Opdivo Diversifies Options In Liver Cancer
Response rate data supports yet another supplemental approval for Opdivo in an underserved tumor type that is becoming more competitive.
- Antisense, Oligonucleotides
- Other Names / Subsidiaries
- Polaris Pharmaceuticals, Inc.
- TDW Pharmaceuticals, Inc.
- DesigneRx Pharmaceuticals, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.